Inflammatix is reimagining molecular diagnostics by developing rapid point-of-care tests that aid in the diagnose of acute in ... fections and sepsis based on our unique immune profiling technology. Approximately $10 billion / year is spent trying to diagnose acute infections, but current methods that focus on ‘finding the bug’ are too slow and are ineffective 70% of the time. In many cases, this approach leaves clinicians with no choice but to treat their patients without a complete and true understanding of their patient’s ailment. Inflammatix has developed a game-changing diagnostic test that reads the immune system and uses proprietary algorithms to generate clinically actionable information on the presence, type (bacterial or viral), and severity of infection in patients in less than 30 minutes. Faster diagnosis means more appropriate antibiotic therapy and level of care decisions, which enable better patient outcomes. Our host response-based diagnostics pipeline includes tests for acute infection and sepsis, emerging infectious diseases, autoimmune diseases, tropical infections, transplant rejection, and other conditions. read more